This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Medline (MDLN) Receives a Buy from Barclays

Tipranks - Tipranks - Thu Nov 5, 3:06AM CST

In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Medline, with a price target of $43.00.

Santangelo covers the Healthcare sector, focusing on stocks such as Cardinal Health, Teva Pharmaceutical, and Hims & Hers Health. According to TipRanks, Santangelo has an average return of 3.5% and a 52.99% success rate on recommended stocks.

In a report released on October 22, Mizuho Securities also maintained a Buy rating on the stock with a $45.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Medline’s latest earnings release for the quarter ending June 27, the company reported a quarterly revenue of $7.69 billion and a net profit of $60 million. In comparison, last year the company earned a revenue of $6.89 billion and had a net profit of $333 million

Based on the recent corporate insider activity of 95 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDLN in relation to earlier this year. Last month, Government Of Singapore Investment Corp Pte Ltd Et, a Major Shareholder at MDLN sold 7,816,987.00 shares for a total of $274,767,093.05.

Read More on MDLN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.